New anesthetic may offer safer sedation for heart valve patients

NCT ID NCT05881291

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a new sedative called ciprofol against the standard drug propofol for general anesthesia in 124 older adults undergoing transcatheter aortic valve replacement (TAVR). The goal was to see if ciprofol causes fewer episodes of low blood pressure after anesthesia. Researchers measured blood pressure changes in the first 15 minutes after sedation and tracked side effects like injection pain.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

ciprofol

What this could lead to

If successful, ciprofol could offer a safer alternative to propofol for anesthesia in heart valve replacement, with fewer drops in blood pressure.

What could go wrong

This is a small, completed phase 4 trial with 124 patients. Results may not apply to all patients, and ciprofol's benefits over propofol may be modest.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AORTIC VALVE STENOSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

aortic valve stenosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • The Second Affiliated Hospital of Zhejiang University anesthesiology department

    Hangzhou, Zhejiang, 310000, China